211 related articles for article (PubMed ID: 9145839)
1. Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats.
Bhamra R; Sa'ad A; Bolcsak LE; Janoff AS; Swenson CE
Antimicrob Agents Chemother; 1997 May; 41(5):886-92. PubMed ID: 9145839
[TBL] [Abstract][Full Text] [Related]
2. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.
Ramaswamy M; Peteherych KD; Kennedy AL; Wasan KM
Antimicrob Agents Chemother; 2001 Apr; 45(4):1184-91. PubMed ID: 11257033
[TBL] [Abstract][Full Text] [Related]
3. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model.
Cannon JP; Fiscella R; Pattharachayakul S; Garey KW; De Alba F; Piscitelli S; Edward DP; Danziger LH
Invest Ophthalmol Vis Sci; 2003 May; 44(5):2112-7. PubMed ID: 12714650
[TBL] [Abstract][Full Text] [Related]
4. Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model.
Goldblum D; Rohrer K; Frueh BE; Theurillat R; Thormann W; Zimmerli S
Ophthalmic Res; 2004; 36(3):172-6. PubMed ID: 15103209
[TBL] [Abstract][Full Text] [Related]
5. Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content.
Kennedy AL; Wasan KM
J Pharm Sci; 1999 Nov; 88(11):1149-55. PubMed ID: 10564063
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies.
Adedoyin A; Bernardo JF; Swenson CE; Bolsack LE; Horwith G; DeWit S; Kelly E; Klasterksy J; Sculier JP; DeValeriola D; Anaissie E; Lopez-Berestein G; Llanos-Cuentas A; Boyle A; Branch RA
Antimicrob Agents Chemother; 1997 Oct; 41(10):2201-8. PubMed ID: 9333048
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.
Wasan KM; Kennedy AL; Cassidy SM; Ramaswamy M; Holtorf L; Chou JW; Pritchard PH
Antimicrob Agents Chemother; 1998 Dec; 42(12):3146-52. PubMed ID: 9835506
[TBL] [Abstract][Full Text] [Related]
8. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model.
Goldblum D; Rohrer K; Frueh BE; Theurillat R; Thormann W; Zimmerli S
Antimicrob Agents Chemother; 2002 Dec; 46(12):3719-23. PubMed ID: 12435667
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis.
Cicogna CE; White MH; Bernard EM; Ishimura T; Sun M; Tong WP; Armstrong D
Antimicrob Agents Chemother; 1997 Feb; 41(2):259-61. PubMed ID: 9021176
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections.
Adedoyin A; Swenson CE; Bolcsak LE; Hellmann A; Radowska D; Horwith G; Janoff AS; Branch RA
Antimicrob Agents Chemother; 2000 Oct; 44(10):2900-2. PubMed ID: 10991885
[TBL] [Abstract][Full Text] [Related]
12. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.
Groll AH; Lyman CA; Petraitis V; Petraitiene R; Armstrong D; Mickiene D; Alfaro RM; Schaufele RL; Sein T; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2006 Oct; 50(10):3418-23. PubMed ID: 17005824
[TBL] [Abstract][Full Text] [Related]
13. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary extraction and accumulation of lipid formulations of amphotericin B.
Matot I; Pizov R
Crit Care Med; 2000 Jul; 28(7):2528-32. PubMed ID: 10921589
[TBL] [Abstract][Full Text] [Related]
15. Penetration of amphotericin B lipid formulations into pleural effusion.
Weiler S; Bellmann-Weiler R; Joannidis M; Bellmann R
Antimicrob Agents Chemother; 2007 Nov; 51(11):4211-3. PubMed ID: 17785511
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B lipid complex.
Rapp RP; Gubbins PO; Evans ME
Ann Pharmacother; 1997 Oct; 31(10):1174-86. PubMed ID: 9337444
[TBL] [Abstract][Full Text] [Related]
17. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2002 Mar; 46(3):834-40. PubMed ID: 11850269
[TBL] [Abstract][Full Text] [Related]
18. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?
Swenson CE; Perkins WR; Roberts P; Ahmad I; Stevens R; Stevens DA; Janoff AS
Antimicrob Agents Chemother; 1998 Apr; 42(4):767-71. PubMed ID: 9559780
[TBL] [Abstract][Full Text] [Related]
20. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
